Peter Strumph

Company: Parvus Therapeutics

Job title: Chief Executive Officer

Seminars:

Tackling Tissue Specificity: The Translational Journey from Antigen Selection to Clinical Proof-of-Concept 2:30 pm

Selecting the antigen of choice for delivery/presentation with MHCII Highlighting data showing tissue specificity, bystander effect, disease modification, and persistence Discussing plans for clinical proof-of-concept for direct measurement of endogenously expanded Treg cellsRead more

day: Conference Day Two